{"nctId":"NCT02392559","briefTitle":"Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders","startDateStruct":{"date":"2016-03-24","type":"ACTUAL"},"conditions":["Heterozygous Familial Hypercholesterolemia"],"count":158,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"EvoMab 420 mg QM","type":"EXPERIMENTAL","interventionNames":["Drug: Evolocumab"]}],"interventions":[{"name":"Evolocumab","otherNames":["AMG 145; EvoMab"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥ 10 to ≤ 17 years of age (before 18th birthday)\n* Diagnosis of heterozygous familial hypercholesterolemia\n* On an approved statin with stable optimized dose for ≥ 4 weeks\n* Other lipid-lowering therapy stable for ≥ 4 weeks (fibrates must be stable for ≥ 6 weeks)\n* Fasting LDL-C ≥ 130 mg/dL (3.4 mmol/L)\n* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)\n\nExclusion Criteria:\n\n* Type 1 diabetes, or type 2 diabetes that is or poorly controlled\n* Uncontrolled hyperthyroidism or hypothyroidism\n* Cholesterylester transfer protein (CETP) inhibitor in the last 12 months, or mipomersen or lomitapide in the last 5 months\n* Previously received evolocumab or any other investigational therapy to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9).\n* Lipid apheresis within the last 12 weeks prior to screening.\n* Homozygous familial hypercholesterolemia","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline to Week 24 in LDL-C","description":"Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from interactive voice response system \\[IVRS\\]), scheduled visit and the interaction of treatment with scheduled visit as covariates. The model uses an unstructured covariance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.23","spread":"3.08"},{"groupId":"OG001","value":"-44.53","spread":"2.17"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline to Mean of Weeks 22 and 24 in LDL-C","description":"Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.87","spread":"2.66"},{"groupId":"OG001","value":"-47.95","spread":"1.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in LDL-C","description":"Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"6.2"},{"groupId":"OG001","value":"-77.5","spread":"4.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in Non-HDL-C","description":"Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.14","spread":"2.87"},{"groupId":"OG001","value":"-41.19","spread":"2.01"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in Apoliprotein-B (ApoB)","description":"Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.37","spread":"2.70"},{"groupId":"OG001","value":"-34.85","spread":"1.88"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in Total Cholesterol/HDL-C Ratio","description":"Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.66","spread":"2.60"},{"groupId":"OG001","value":"-34.96","spread":"1.82"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in ApoB:ApoA1 Ratio","description":"Least squares mean is from the repeated measures model which includes treatment group, stratification factors of age and screening LDL-C (from IVRS), scheduled visit and the interaction of treatment with scheduled visit as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"2.80"},{"groupId":"OG001","value":"-37.02","spread":"1.95"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation (DC), Fatal TEAEs, and Device-Related TEAEs","description":"An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have a causal relationship with study treatment. An SAE is defined as an adverse event that: is fatal; is a life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other medically important serious event. Events were graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grading scale (1=mild; 2=moderate; 3=severe; 4=life-threatening; 5=death). Events were defined as treatment emergent if they occurred after the first dose of study drug and up to and including 30 days after the last dose or the end of study date, whichever is earlier.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maximum Post-Baseline Laboratory Toxicities of Grade ≥ 3","description":"Laboratory toxicity grading was based on NCI CTCAE grading. Grade 3 indicates severe toxicity and Grade 4 indicates life-threatening toxicity. Values representing a worsening from baseline are shown.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Over Time in Systolic Blood Pressure","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"11.3"},{"groupId":"OG001","value":"-0.7","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"10.3"},{"groupId":"OG001","value":"0.3","spread":"9.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"7.7"},{"groupId":"OG001","value":"0.1","spread":"10.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"10.9"},{"groupId":"OG001","value":"1.1","spread":"10.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"11.4"},{"groupId":"OG001","value":"0.6","spread":"10.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Over Time in Diastolic Blood Pressure","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"9.5"},{"groupId":"OG001","value":"-1.5","spread":"7.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"10.0"},{"groupId":"OG001","value":"0.5","spread":"8.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"7.6"},{"groupId":"OG001","value":"-0.6","spread":"7.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"9.3"},{"groupId":"OG001","value":"2.9","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"9.0"},{"groupId":"OG001","value":"0.3","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Over Time in Heart Rate","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"11.0"},{"groupId":"OG001","value":"0.1","spread":"10.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"11.5"},{"groupId":"OG001","value":"-1.3","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"10.3"},{"groupId":"OG001","value":"1.1","spread":"11.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"13.5"},{"groupId":"OG001","value":"-0.6","spread":"11.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"13.0"},{"groupId":"OG001","value":"-1.8","spread":"11.8"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Testing Positive for Anti-Evolocumab Antibodies","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Evolocumab Concentrations Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22400","spread":"14700"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64900","spread":"34400"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25800","spread":"19200"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["Nasopharyngitis","Headache","Gastroenteritis","Influenza","Upper respiratory tract infection"]}}}